newsfilter
← Latest News
Business Wire·

Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection

-- Distribution partners stocked with product and ready to sell into estimated $2 billion market -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company"), a biopharmaceutical company focused on